Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

The goal of this single-arm, prospective clinical trial is to evaluate the safety and efficacy of neoadjuvant therapy combining sintilimab with stereotactic body radiation therapy (SBRT) in patients with resectable hepatocellular carcinoma (HCC) with branch portal vein tumor thrombus. The main questions it aims to answer are: 1. Is the combination of sintilimab and SBRT safe as neoadjuvant therapy? 2. How effective is this combination in treating resectable HCC with branch PVTT? Participants will be given a combination treatment of sintilimab and SBRT. Researchers will monitor their health co

Trial Details

NCT ID
NCT06664996
Phase
PHASE2
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • stereotactic body radiation therapy (SBRT)
  • Sintilimab (approved)
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Age greater than 18 years, regardless of gender.
  • Voluntary participation, as evidenced by signed informed consent, with the willingness and ability to comply with scheduled visits, treatment plans…
  • Diagnosis of hepatocellular carcinoma confirmed either histologically, cytologically, or based on characteristic imaging features (ultrasound, CT, …
  • Presence of measurable disease lesions per modified RECIST (mRECIST) criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →